Raldesy Shortage: What Providers and Prescribers Need to Know in 2026

Raldesy (trazodone hydrochloride oral solution, 10 mg/mL) received FDA approval in 2024 as the first and only FDA-approved liquid formulation of trazodone. It was developed specifically for patients who cannot swallow tablets — a clinically underserved population that includes elderly patients, individuals with dysphagia, and those in care settings where liquid administration is necessary. However, as a new brand-only product, Raldesy presents real access challenges for patients in 2026. This guide gives prescribers a clear-eyed view of the current situation and practical steps to support their patients.

Current Availability Status: Not an Official Shortage, But Still a Problem

As of 2026, Raldesy is not listed on either the FDA Drug Shortages Database or the ASHP Drug Shortage List. However, prescribers should be aware that their patients are likely to encounter difficulty finding Raldesy in stock. This is a distribution and formulary issue, not a manufacturing supply problem.

The core issues driving limited pharmacy availability include:

Recent market entry (2024 approval): Most pharmacies default to stocking products with established demand. Newer specialty liquids take time to build consistent shelf presence.

Brand-only formulation: No generic liquid trazodone exists. Pharmacies that see limited demand for the brand will not automatically stock it.

Formulary restrictions: Medicare Part D generally excludes Raldesy. Commercial payers frequently require prior authorization for brand-only antidepressants, especially when a generic tablet exists.

High retail price: At $390–$456 per 150 mL bottle (30-day supply), patients without assistance programs face significant out-of-pocket burden, leading to prescription abandonment.

Clinical Context: Who Is Raldesy Indicated For?

Raldesy is FDA-approved for the treatment of major depressive disorder (MDD) in adults. It is not approved for pediatric patients. As a serotonin antagonist and reuptake inhibitor (SARI), trazodone works by inhibiting serotonin reuptake and blocking 5-HT2A and 5-HT2C receptors, along with histamine H1 and alpha-1 adrenergic receptors. This mechanism provides antidepressant effects while also addressing insomnia and anxiety — key comorbidities in MDD — without the sexual dysfunction commonly associated with SSRIs and SNRIs.

The liquid formulation addresses a genuine unmet need. Previously, clinicians prescribing trazodone to patients who cannot swallow tablets relied on compounded liquid preparations from 503A pharmacies — preparations that are not FDA-approved and may vary in quality and consistency. Raldesy provides a standardized, FDA-approved alternative.

Navigating Prior Authorization for Raldesy

Most commercial insurers will require prior authorization (PA) for Raldesy, given that generic trazodone tablets are available and inexpensive. When submitting a PA request, include the following in your clinical documentation:

Documented diagnosis of MDD (ICD-10: F32.x or F33.x)

Clear medical necessity for liquid formulation: dysphagia diagnosis, post-surgical status, cognitive impairment, or caregiver-administered medication context

Documentation that the patient cannot reliably take tablets (e.g., swallowing evaluation results, nursing notes, or clinical observations)

Note that compounded liquid trazodone is not FDA-approved and carries quality and consistency risks compared to Raldesy

Commercial PA requests are typically decided within 24–72 hours. If denied, appeals supported by clinical documentation succeed at higher rates.

Clinical Alternatives When Raldesy Is Unavailable

If Raldesy is not accessible for your patient, the following evidence-based alternatives merit consideration:

Compounded liquid trazodone: Available from 503A-registered compounding pharmacies. Not FDA-approved, but widely used as a bridge. Prescribers should verify the compounding pharmacy's quality and compliance status.

Sertraline oral concentrate (20 mg/mL): FDA-approved, generic available, widely stocked. Appropriate when liquid administration is the primary need and the trazodone SARI mechanism is not specifically required.

Escitalopram oral solution (1 mg/mL): FDA-approved liquid SSRI. Well-tolerated; generic available.

Mirtazapine ODT (15 mg, 30 mg, 45 mg): Orally disintegrating tablet that dissolves on the tongue. Helpful for patients with dysphagia. Sedating, similar profile to trazodone for sleep and appetite. Generic available.

Generic trazodone tablets (crushed or split): Immediate-release trazodone tablets can be crushed and mixed with food or water in appropriate clinical contexts. Consult with pharmacy for guidance on stability.

Prescribing Notes and Safety Considerations

Key prescribing notes for Raldesy in 2026:

Boxed warning: Increased risk of suicidal thoughts and behaviors in pediatric and young adult patients under 24 years of age. Monitor closely during initiation and dose changes.

Starting dose: 150 mg/day orally in divided doses, taken after a meal or light snack; titrate by 50 mg/day every 3–4 days as tolerated

Maximum dose: 400 mg/day for outpatients; 600 mg/day for inpatients

Contraindicated within 14 days of MAOI use (including linezolid and IV methylene blue)

CYP3A4 interactions: Strong inhibitors may increase trazodone exposure; strong inducers may reduce efficacy

Priapism risk: Counsel male patients; caution in those with predisposing conditions (sickle cell anemia, multiple myeloma, leukemia, or penile anatomical abnormalities)

Discard any unused Raldesy remaining in the bottle 20 days after first opening

Helping Your Patients Access Raldesy

Providers can direct patients to medfinder for providers — a service that contacts pharmacies on patients' behalf to identify which ones can fill the prescription. This reduces the burden on patients who may not be capable of making repeated phone calls. Also direct patients to the Raldesy Liquid Innovation With Care Patient Support Program (877-384-1417) for copay assistance and patient assistance program enrollment.